Description
The abstract notes that many candidates targeting established AD pathways have failed in trials, creating a paradox between pathological understanding and therapeutic success. This disconnect suggests fundamental gaps in translating mechanistic knowledge to effective treatments.
Gap type: contradiction Source paper: Unveiling Alzheimer’s disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies. (2026, Ageing research reviews, PMID:41386339)
Resolution criteria
Resolved when failed amyloid/tau therapeutic programs are explained by a testable failure taxonomy tied to patient stage, target engagement, biomarker response, and downstream neurodegeneration. Required evidence: meta-analysis of clinical trial datasets with amyloid/tau PET or CSF engagement, timing relative to disease stage, dose exposure, inflammatory and neuronal injury biomarkers, and cognitive outcomes. Closure requires identifying reproducible failure modes and prospective criteria for selecting when amyloid or tau targeting should or should not work.
Evidence summary
Resolved by hypothesis h-var-66156774e7: TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration. Score: 0.892. Supporting PMIDs: 37099634, 31932797, 36306735, 28802038, 41757182.